How Is Gastroparesis Monitored in Ozempic Users?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Science to Specific Patient Concerns

If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis. Decades of pharmacovigilance have established that certain medications can slow gastric emptying, and recent reports have intensified scrutiny of GLP-1 agonists in this context. This page outlines the follow-up tests and monitoring guidelines relevant to Ozempic-associated gastroparesis.

Ozempic and Gastrointestinal Adverse Reactions: A Bridge to Legal Context

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its prescribing information documents a range of gastrointestinal adverse reactions that occur at significantly higher rates than with placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 32.7% of patients receiving Ozempic 0.5 mg and 36.4% of those receiving Ozempic 1 mg, compared to 15.3% in the placebo group (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and diarrhea occurred during dose escalation, and more patients discontinued treatment due to these reactions: 3.1% on 0.5 mg and 3.8% on 1 mg, versus 0.4% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in at least 5% of Ozempic-treated patients include nausea (20.3% on 1 mg vs. 6.1% on placebo), vomiting (9.2% vs. 2.3%), diarrhea (8.8% vs. 1.9%), abdominal pain (5.7% vs. 4.6%), and constipation (3.1% vs. 1.5%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal reactions occurring at frequencies below 5% include dyspepsia (2.7% on 1 mg), eructation (1.1%), flatulence (1.5%), gastroesophageal reflux disease (1.5%), and gastritis (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data establish a clear bridge from general health education to the specific adverse effects that may lead to legal claims.

Gastroparesis: Symptoms, Diagnosis, and Link to Ozempic

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical presentation of gastroparesis overlaps significantly with the gastrointestinal adverse effects listed in Ozempic's label, including nausea, vomiting, abdominal pain, and dyspepsia. Mechanistically, GLP-1 receptor agonists like semaglutide slow gastric motility and delay gastric emptying as part of their pharmacodynamic action. This effect is dose-dependent and can be pronounced, particularly during initial treatment or dose escalation. The reported adverse reactions of nausea, vomiting, and abdominal pain in clinical trials may reflect this underlying delay in gastric emptying. In some patients, these effects may persist or worsen, potentially leading to a clinical picture consistent with gastroparesis. The label notes that in a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) compared to the 1 mg dose (30.8%), suggesting a dose-response relationship (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). For patients in Michigan who have developed gastroparesis symptoms after using Ozempic, several legal considerations arise.

Michigan Statute of Limitations for Ozempic-Related Gastroparesis Claims

The statute of limitations for personal injury claims in Michigan is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. For product liability claims involving prescription drugs, the clock may start when the patient knew or should have known that the drug caused their harm. Given that Ozempic's label does not explicitly list gastroparesis as a known adverse reaction, patients may not immediately connect their symptoms to the medication. The timeline between exposure and documented harm is critical: symptoms often emerge during dose escalation, but a formal diagnosis of gastroparesis may require gastric emptying studies and specialist evaluation, which can take months. This delay can affect the statute of limitations, as the injury may not be 'discovered' until a diagnosis is confirmed. The adequacy of warnings regarding Ozempic and gastroparesis is a central risk anchor. The label describes gastrointestinal adverse reactions in general terms but does not specifically warn of gastroparesis as a distinct condition. While the label lists nausea, vomiting, abdominal pain, and dyspepsia, it does not inform patients or prescribers that these symptoms may represent gastroparesis or that the drug can cause delayed gastric emptying severe enough to mimic or induce this disorder. This gap in warning may be relevant in legal claims, as Michigan law requires manufacturers to provide adequate warnings of known or reasonably foreseeable risks. If a patient develops gastroparesis and the label did not alert them to this possibility, the manufacturer may be held liable for failure to warn.

Legal Considerations for Affected Patients in Michigan

Attorney-related considerations for affected patients include the need to document the timeline of Ozempic use, symptom onset, and medical diagnosis. Patients should retain all prescription records, pharmacy receipts, and medical notes. A gastroenterologist's diagnosis of gastroparesis, confirmed by gastric emptying scintigraphy, is essential evidence. The link between Ozempic and gastroparesis may be supported by the temporal relationship: symptoms appearing after starting the drug, worsening with dose increases, and possibly improving after discontinuation. Expert testimony from a gastroenterologist or pharmacologist can help establish the mechanistic pathway, as GLP-1 agonists are known to slow gastric emptying. In Michigan, product liability claims can be brought under theories of defective design, failure to warn, or negligence. The statute of limitations may be tolled if the patient was unaware of the connection, but this is fact-specific and requires prompt legal consultation. In summary, Ozempic's label documents a high incidence of gastrointestinal adverse reactions that overlap with gastroparesis symptoms, and the drug's mechanism of delaying gastric emptying provides a plausible link to this condition. Michigan patients who develop gastroparesis after using Ozempic should be aware of the three-year statute of limitations, which may begin when the injury is discovered. The adequacy of warnings is a key issue, as the label does not specifically mention gastroparesis. Legal action may be viable if the manufacturer failed to warn of this risk. Patients should seek medical evaluation and legal advice promptly to preserve their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Michigan?

In Michigan, the statute of limitations for personal injury claims, including product liability, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, the clock may start when the patient knew or should have known that the drug caused their harm. Given that symptoms may not be immediately linked to the medication, it is crucial to consult an attorney promptly to preserve your rights.

Does Ozempic's label warn about gastroparesis?

No, Ozempic's label does not explicitly list gastroparesis as a known adverse reaction. It describes gastrointestinal adverse reactions such as nausea, vomiting, abdominal pain, and dyspepsia, but does not inform patients or prescribers that these symptoms may represent gastroparesis or that the drug can cause delayed gastric emptying severe enough to mimic or induce this disorder. This gap in warning may be relevant in failure-to-warn claims.

What evidence is needed for an Ozempic gastroparesis lawsuit in Michigan?

Key evidence includes prescription records, pharmacy receipts, medical notes, and a gastroenterologist's diagnosis of gastroparesis confirmed by gastric emptying scintigraphy. Documentation of the temporal relationship between Ozempic use and symptom onset, worsening with dose increases, and possible improvement after discontinuation is also important. Expert testimony from a gastroenterologist or pharmacologist can help establish the mechanistic link.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.